• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
Generic Name:  amifampridine phosphate
Trade Name:  N/A
Date Designated:  03/03/2015
Orphan Designation:  Treatment of congenital myasthenic syndromes
Orphan Designation Status:  Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Marketing Approval Date:  N/A
Approved Labeled Indication:  
Exclusivity End Date:    N/A
Catalyst Pharmaceuticals
(dba Catalyst Pharmaceutical Partner, Inc)
Suite 1500
Coral Gables, Florida 33134

The sponsor address listed is the last reported by the sponsor to OOPD.